Sugi Predict

Sugi Predict / Targets / ACVR2A

ACVR2A

Activin receptor type-2A · P27037 · ACVR2A on Sugi Atlas →

4,887 patent compounds predicted against ACVR2A, 2,882 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10233441 SCHEMBL10233441 0.53 15/20
SCHEMBL3265099 SCHEMBL3265099 0.49 12/20
SCHEMBL6115634 SCHEMBL6115634 0.41 6/20
SCHEMBL561555 SCHEMBL561555 0.37 6/20
SCHEMBL12461301 SCHEMBL12461301 0.53 5/20
SCHEMBL4332306 SCHEMBL4332306 0.47 5/20
SCHEMBL744054 SCHEMBL744054 0.47 5/20
SCHEMBL4342454 SCHEMBL4342454 0.46 5/20
SCHEMBL94423 SCHEMBL94423 0.43 5/20
SCHEMBL988741 SCHEMBL988741 0.36 5/20
SCHEMBL4339798 SCHEMBL4339798 0.50 4/20
SCHEMBL3477780 SCHEMBL3477780 0.49 4/20
SCHEMBL4885901 SCHEMBL4885901 0.41 4/20
SCHEMBL12679982 SCHEMBL12679982 0.38 4/20
SCHEMBL2896067 SCHEMBL2896067 0.36 4/20
SCHEMBL2897122 SCHEMBL2897122 0.36 4/20
SCHEMBL3674446 SCHEMBL3674446 0.35 4/20
SCHEMBL4347235 SCHEMBL4347235 0.54 3/20
SCHEMBL4558600 SCHEMBL4558600 0.54 3/20
SCHEMBL4796523 SCHEMBL4796523 0.54 3/20

Clinical trials — most relevant to ACVR2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients PHASE3UNKNOWN
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor PHASE1/PHASE2COMPLETED
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) PHASE2COMPLETED
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy PHASE1COMPLETED
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults PHASE1NOT_YET_RECRUITING
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension nanCOMPLETED
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers nanCOMPLETED
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension nanUNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
The PAH Platform for Deep Phenotyping in Korean Subjects nanUNKNOWN
StratosPHere (Non-interventional Study) nanCOMPLETED
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension. nanRECRUITING
National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension nanUNKNOWN
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia nanRECRUITING
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals nanRECRUITING
Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia nanNOT_YET_RECRUITING
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH nanWITHDRAWN
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension nanCOMPLETED
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension nanCOMPLETED
Luspatercept in Metastatic AGCT of the Ovary nanCOMPLETED
Influence of Sarcopenia on the Course of the Diseases nanRECRUITING
Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital nanNOT_YET_RECRUITING
Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension nanCOMPLETED
Activin A and Inhibin A in Predicting Outcome of Pregnancies of Unknown Location After Assisted Reproductive Technology nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ACVR2A binder may also engage these)

ProteinNameSimilarity
P27038 — 1.000 P27038 →
Q28043 — 1.000 Q28043 →
Q90669 — 1.000 Q90669 →
P38444 — 1.000 P38444 →
Q28560 — 1.000 Q28560 →
P27039 — 1.000 P27039 →
P27041 — 0.995 P27041 →
Q90670 — 0.992 Q90670 →
P27040 — 0.991 P27040 →
P38445 — 0.991 P38445 →
ACVR2B Activin receptor type-2B 0.990 landscape →
P38438 — 0.989 P38438 →
Q95126 — 0.989 Q95126 →
Q66T47 — 0.988 Q66T47 →
Q90999 — 0.985 Q90999 →
Q62312 — 0.981 Q62312 →
TGFBR2 TGF-beta receptor type-2 0.978 landscape →
Q9ESL4 — 0.970 Q9ESL4 →
Q01974 — 0.969 Q01974 →
Q9Z138 — 0.969 Q9Z138 →
P00535 — 0.966 P00535 →
MAP3K20 Mitogen-activated protein kinase kinase kinase 20 0.966 landscape →
Q8BPM2 — 0.966 Q8BPM2 →
ARAF Serine/threonine-protein kinase A-Raf 0.966 landscape →
P00534 — 0.964 P00534 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.964 landscape →
P28028 — 0.964 P28028 →
Q4V8A9 — 0.964 Q4V8A9 →
Q9NPH3 — 0.963 Q9NPH3 →
MAP3K15 Mitogen-activated protein kinase kinase kinase 15 0.963 landscape →